Clinical Trial Update: An Investigational Scan (Ga-68 PSMA-11 PET/CT) for Detection of Disease Recurrence or Progression in Patients With Glioma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating Gallium-68 PSMA-11 PET/CT for detecting recurrence or progression in high-grade gliomas (WHO Grade 3 and Grade 4).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Astrocytoma
• Anaplastic Oligodendroglioma
• Glioblastoma

Drugs mentioned

• Ga-68 PSMA-11 (Gallium-68 labeled PSMA-11 radiopharmaceutical imaging agent)

Snippet

Sponsor: Mayo Clinic | Conditions: WHO Grade 3 Glioma, WHO Grade 4 Glioma | Phase 2 | Status: RECRUITING